Raltegravir-based Postnatal HIV Prophylaxis Therapy in a Neonate After in Utero Dolutegravir Exposure

We present a case report of a neonate receiving raltegravir-based postnatal HIV prophylaxis after in utero dolutegravir exposure. High levels of raltegravir and dolutegravir can potentially cause bilirubin toxicity as they compete for albumin binding and follow the same metabolic pathway through UGT...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Tom G., van Aerde, Koen J., Colbers, Angela, Burger, David M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
HIV Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740601/
https://www.ncbi.nlm.nih.gov/pubmed/35017453
http://dx.doi.org/10.1097/INF.0000000000003364

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8740601/
https://www.ncbi.nlm.nih.gov/pubmed/35017453
http://dx.doi.org/10.1097/INF.0000000000003364

Ejemplares similares